Quarterly report pursuant to Section 13 or 15(d)

Merger (Details)

v3.21.2
Merger (Details)
$ / shares in Units, $ in Thousands
3 Months Ended 9 Months Ended
Nov. 05, 2020
Milestone
Right
Director
$ / shares
shares
Sep. 30, 2021
USD ($)
Milestone
$ / shares
shares
Sep. 30, 2021
USD ($)
Milestone
$ / shares
shares
Dec. 31, 2020
$ / shares
shares
Nov. 19, 2020
shares
Jun. 29, 2020
shares
Merger Information [Abstract]            
Common stock issued (in shares) 7,091,878          
Common stock, par value (in dollars per share) | $ / shares $ 0.0001 $ 0.0001 $ 0.0001 $ 0.0001    
Common stock issued (in shares)   17,295,434 17,295,434 10,882,495    
Exchange ratio 1.0565   1.0565      
Number of directors required to complete transaction | Director 1          
Contingent Value Rights Agreement [Abstract]            
Contingent value rights payment period   15 years        
Sum of cash consideration paid by a third party 75.00%          
Parent IP deal period   10 years        
Payments due under CVR Agreement | $   $ 91 $ 91      
Number of milestones accrued | Milestone 0 0 0      
Number of potential milestones | Milestone 0 0 0      
Securities Purchase Agreement [Member]            
Merger Information [Abstract]            
Common stock issued (in shares) 3,749,992       3,749,992 1,249,996
Former Stockholders and Option Holders of Private Ocuphire [Member]            
Merger Information [Abstract]            
Percentage ownership 86.60%          
Rexahn [Member]            
Merger Information [Abstract]            
Percentage ownership 13.40%          
Contingent Value Rights Agreement [Abstract]            
Number of contingent value right received per common stock | Right 1          
Rexahn [Member] | BioSense Global LLC [Member]            
Contingent Value Rights Agreement [Abstract]            
Percentage of payments received by Rexahn or its affiliates 90.00%          
Rexahn [Member] | Zhejiang HaiChang Biotechnology Co., Ltd [Member]            
Contingent Value Rights Agreement [Abstract]            
Percentage of payments received by Rexahn or its affiliates 90.00%